A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma

Trial Profile

A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Iboctadekin (Primary) ; Ofatumumab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2016 Results analyzing safety and biological activity, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 15 Apr 2016 Dose given to patient is changed from 3-100 µg/kg/day to 3-30 µg/kg/day as per ClinicalTrials.gov record.
    • 15 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top